NCT05578352

The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Nanjing First Hospital, Nanjing Medical University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Premix insulin is widely used, with high proportion of positive insulin autoimmune antibody in patients with type 2 diabetes. The positive insulin autoimmune antibody may affect blood glucose control. We aim to explore the management for the positive insulin autoimmune antibody and blood glucose control in these patients, and investigate the immune cells changes with the change of different glucose lowering drugs.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
OTHER	Add oral hyppoglycemia drug	Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
OTHER	Add GLP-1 receptor agonist	Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
OTHER	Change insulin	Change premix insulin to long-acting insulin

Timeline

• Start date: 2022-08-05
• Primary completion: 2023-01-31
• Completion: 2023-01-31
• First posted: 2022-10-13
• Last updated: 2022-10-13

Locations

1 site across 1 country: China